Low-molecular-weight heparin good therapy for cancer patients
Cancer Consultants, an oncology resource center, is reporting that prophylactic use of nadroparin, a low-molecular-weight heparin, significantly reduces the incidence of thromboembolic events in patients who have cancer and are undergoing chemotherapy. This finding was presented this week by Italian researchers with the PROTECHT Study, at the annual meeting of the American Society of Hemotology.